NCT01456104View on ClinicalTrials.gov

Immune Responses to Autologous Langerhans-type Dendritic Cells Electroporated With mRNA Encoding a Tumor-associated Antigen in Patients With Malignancy: A Single-arm Phase I Trial in Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

October 17, 2011

Primary Completion Date

January 12, 2023

Study Completion Date

January 12, 2023

Conditions
Melanoma
Interventions
BIOLOGICAL

Langerhans-type dendritic cells (a.k.a. Langerhans cells or LCs)

Patients will receive a total of 5 vaccinations, comprising a primary immunization followed by four boosters at 3 week intervals with a window of ± 4 days. Vaccines will be dosed at 10x106 LCs per vaccine x 5.

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors
collaborator

Rockefeller University

OTHER

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT01456104 - Immune Responses to Autologous Langerhans-type Dendritic Cells Electroporated With mRNA Encoding a Tumor-associated Antigen in Patients With Malignancy: A Single-arm Phase I Trial in Melanoma | Biotech Hunter | Biotech Hunter